An Open-Label, Single-Sequence Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986141 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs BMS 986141 (Primary) ; Rifampicin
- Indications Thrombosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 21 Feb 2017 Status changed from active, no longer recruiting to completed.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
- 12 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.